Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2016 by M.D. Anderson Cancer Center
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01751425
First received: December 14, 2012
Last updated: December 5, 2016
Last verified: December 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Study Completion Date: No date given
  Estimated Primary Completion Date: July 2019 (Final data collection date for primary outcome measure)